<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04309214</url>
  </required_header>
  <id_info>
    <org_study_id>Kanso 2</org_study_id>
    <nct_id>NCT04309214</nct_id>
  </id_info>
  <brief_title>Market Research - Acceptability Study for New MCT Fat Products</brief_title>
  <official_title>Market Research - Acceptability Study for a Range of New MCT Based Products (Dr Schär - Kanso) Kanso DeliMCT 53% (Cream) Kanso DeliMCT 28% (Tomato or Mushroom) Kanso DeliMCT 21% (Cacaobar)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Schär AG / SPA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Schär AG / SPA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a market research, observational study to evaluate the tolerability and acceptability
      of MCT supplements for young children, young people and adults with intractable epilepsy,
      GLUT-1 or PDHD from 3 years to adulthood.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 26, 2018</start_date>
  <completion_date type="Actual">January 21, 2019</completion_date>
  <primary_completion_date type="Actual">January 21, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gastrointestinal tolerance</measure>
    <time_frame>7 days for each product, maximum 25 days</time_frame>
    <description>Questionnaire detailing any GI symptoms, severity and change from usual The collection of daily data about the gastrointestinal tolerance of the product</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Product compliance</measure>
    <time_frame>7 days for each product, maximum 25 days</time_frame>
    <description>Daily questionnaire on amounts offered and amounts actually consumed, compared to recommended amount.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Product palatability</measure>
    <time_frame>7 days for each product, maximum 25 days</time_frame>
    <description>Questionnaire data captured to evaluate taste</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Product acceptability</measure>
    <time_frame>7 days for each product, maximum 25 days</time_frame>
    <description>Brief tick-box questionnaire on overall liking and acceptability of product</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Ketosis</condition>
  <condition>Epilepsy</condition>
  <condition>Fatty Acid Oxidation Disorder</condition>
  <condition>Malabsorption</condition>
  <condition>Ketogenic Diet</condition>
  <condition>Medium Chain Triglycerides</condition>
  <arm_group>
    <arm_group_label>MCT fats</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MCT fats to be consumed, one portion per day to ensure tolerance and compliance to the product whilst support the dietary management for a range if disease states namely, the ketogenic diet, fatty acid oxidation disorders and malabsorption.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>MCT fats</intervention_name>
    <description>Subjects will be asked to take 3 new MCT products for 7 days each over a 25 day period</description>
    <arm_group_label>MCT fats</arm_group_label>
    <other_name>medium chain triglycerides</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of epilepsy requiring a ketogenic or a specialist diet as part of their
             treatment.

          -  Subjects new to taking or who are already taking an MCT product and are willing to try
             each of the 3 study products for 7 days each. 21 days taking product with 2 days
             between each new product trialled.

          -  Those patients who have been taking MCT in their diet should do so for a minimum of 4
             weeks before commencement of the study.

          -  Patients aged 3 years of age to adulthood.

          -  Written informed consent obtained from patient or parental caregiver.

        Exclusion Criteria:

          -  Presence of serious concurrent illness

          -  Investigator's uncertainty about the willingness or ability of the patient to comply
             with the protocol requirements

          -  Participation in any other studies involving investigational or marketed products
             concomitantly or within two weeks prior to entry into the study

          -  Any patients having taken antibiotics over the previous 2 weeks leading up to the
             study

          -  Patients already on and MCT product who have been taking it in their diet for less
             than 4 weeks

          -  Patients less than 3 years of age

          -  Patients over 20 years.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Royal Aberdeen Children's Hospital</name>
      <address>
        <city>Aberdeen</city>
        <state>Grampian</state>
        <zip>AB25 2ZG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 9, 2020</study_first_submitted>
  <study_first_submitted_qc>March 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2020</study_first_posted>
  <last_update_submitted>March 12, 2020</last_update_submitted>
  <last_update_submitted_qc>March 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malabsorption Syndromes</mesh_term>
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Ketosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>This study will be used for the registration and reimbursement for the products used as foods for special medical purposes.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

